Merck: EU approves treatment for lung cancer
(CercleFinance.com) - Merck has announced that the European Commission (EC) has approved KEYTRUDA monotherapy for the adjuvant treatment of adult non-small cell lung cancer (NSCLC) patients at high risk of recurrence, after complete resection and platinum-based chemotherapy.
This EC approval follows the positive recommendation of the Committee for Medicinal Products for Human Use received in September 2023 and was based on the results of the phase 3 KEYNOTE-091 trial.
At a median follow-up time of 46.7 months, KEYTRUDA demonstrated a clinically significant improvement in disease-free survival (DFS) in patients who received adjuvant chemotherapy, reducing the risk of disease recurrence or death by 24%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This EC approval follows the positive recommendation of the Committee for Medicinal Products for Human Use received in September 2023 and was based on the results of the phase 3 KEYNOTE-091 trial.
At a median follow-up time of 46.7 months, KEYTRUDA demonstrated a clinically significant improvement in disease-free survival (DFS) in patients who received adjuvant chemotherapy, reducing the risk of disease recurrence or death by 24%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.